stomach neoplasms

Summary

Summary: Tumors or cancer of the STOMACH.

Articles from Journal RESEARCH

Top Publications

  1. ncbi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
  2. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
  3. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  4. ncbi Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
    J S Macdonald
    St Vincent's Comprehensive Cancer Center, New York, USA
    N Engl J Med 345:725-30. 2001
  5. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
  6. ncbi Helicobacter pylori infection and the development of gastric cancer
    N Uemura
    Department of Gastroenterology, Kure Kyosai Hospital, Kure City, Japan
    N Engl J Med 345:784-9. 2001
  7. ncbi Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
    Tetsuya Ueda
    Department of Molecular Virology, Immunology, Ohio State University, Columbus, OH 43210, USA
    Lancet Oncol 11:136-46. 2010
  8. pmc Incidence and mortality of gastric cancer in China
    Ling Yang
    National Office for Cancer Prevention and Control, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
    World J Gastroenterol 12:17-20. 2006
  9. ncbi Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Yung Jue Bang
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
    Lancet 379:315-21. 2012
  10. ncbi Gastric cancer
    Henk H Hartgrink
    Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands
    Lancet 374:477-90. 2009

Research Grants

Detail Information

Articles from Journal RESEARCH1

Publications291 found, 100 shown here

  1. ncbi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
    ....
  2. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
    ..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
  3. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  4. ncbi Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
    J S Macdonald
    St Vincent's Comprehensive Cancer Center, New York, USA
    N Engl J Med 345:725-30. 2001
    ..CONCLUSIONS: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection...
  5. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
    ....
  6. ncbi Helicobacter pylori infection and the development of gastric cancer
    N Uemura
    Department of Gastroenterology, Kure Kyosai Hospital, Kure City, Japan
    N Engl J Med 345:784-9. 2001
    ..Although many studies have found an association between Helicobacter pylori infection and the development of gastric cancer, many aspects of this relation remain uncertain...
  7. ncbi Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
    Tetsuya Ueda
    Department of Molecular Virology, Immunology, Ohio State University, Columbus, OH 43210, USA
    Lancet Oncol 11:136-46. 2010
    ..We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer...
  8. pmc Incidence and mortality of gastric cancer in China
    Ling Yang
    National Office for Cancer Prevention and Control, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
    World J Gastroenterol 12:17-20. 2006
    ....
  9. ncbi Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Yung Jue Bang
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
    Lancet 379:315-21. 2012
    ..We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with stage II-IIIB gastric cancer...
  10. ncbi Gastric cancer
    Henk H Hartgrink
    Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands
    Lancet 374:477-90. 2009
    ....
  11. pmc Circulating microRNAs in plasma of patients with gastric cancers
    M Tsujiura
    Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii cho, Kawaramachihirokoji, Kamigyo ku, Kyoto 602 8566, Japan
    Br J Cancer 102:1174-9. 2010
    ..We examined plasma microRNA (miRNA) concentrations from patients with gastric cancers (GCs) to assess their clinical application for diagnosing and monitoring diseases...
  12. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
    ..Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer...
  13. ncbi MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta
    Yoshiyuki Tsukamoto
    Department of Molecular Pathology, Faculty of Medicine and Institute of Scientific Research, Oita University, Oita, Japan
    Cancer Res 70:2339-49. 2010
    ..Taken together, we propose that miR-375 is a candidate tumor suppressor miRNA in gastric carcinoma...
  14. pmc Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma
    Jingchun Jin
    Department of Pathology, YanBian University Medical College, Yanji City, Jilin Province, PR China
    Diagn Pathol 7:135. 2012
    ..It has been suggested that Ezrin expression plays an important role in tumor metastasis. This study is aimed to investigate the clinicopathological significance of Ezrin overexpression in gastric adenocarcinomas...
  15. ncbi Screening for gastric cancer in Asia: current evidence and practice
    Wai K Leung
    Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong, China
    Lancet Oncol 9:279-87. 2008
    ..At present, there is a paucity of quality data from Asia to lend support for screening for gastric cancer...
  16. ncbi Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
    Atsushi Ohtsu
    National Cancer Center, Hospital East, Kashiwa, Chiba, Japan
    J Clin Oncol 29:3968-76. 2011
    ....
  17. ncbi Helicobacter pylori and gastrointestinal tract adenocarcinomas
    Richard M Peek
    Division of Gastroenterology, Vanderbilt University School of Medicine, Medical Center North, Nashville, Tennessee 37232 2279, USA
    Nat Rev Cancer 2:28-37. 2002
    ....
  18. ncbi Capecitabine and oxaliplatin for advanced esophagogastric cancer
    David Cunningham
    Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom
    N Engl J Med 358:36-46. 2008
    ..We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer...
  19. ncbi Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues
    Junming Guo
    Ningbo University School of Medicine, Ningbo 315211, Zhejiang Province, China
    J Gastroenterol Hepatol 24:652-7. 2009
    ..MicroRNAs (miRNAs) play important roles in carcinogenesis. The global miRNA expression profile of gastric cancer has not been reported. The purpose of the present study was to determine the miRNA expression profile of gastric cancer...
  20. pmc A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma
    Christian C Abnet
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Genet 42:764-7. 2010
    ..19 x 10(-15); OR = 1.57), and for those in the noncardia stomach it was absent (P = 0.44; OR = 1.05). Our findings at 10q23 could provide insight into the high incidence of both cancers in China...
  21. ncbi Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
    Ilfet Songun
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Lancet Oncol 11:439-49. 2010
    ..The aim of the study was to assess the effect of D2 compared with D1 surgery on disease recurrence and survival in patients treated with curative intent...
  22. pmc Pathogenesis of Helicobacter pylori infection
    Johannes G Kusters
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Clin Microbiol Rev 19:449-90. 2006
    ..This review focuses on the microbiological, clinical, immunological, and biochemical aspects of the pathogenesis of H. pylori...
  23. pmc Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth
    Michael Quante
    Division of Digestive and Liver Diseases, Columbia University, New York, NY 10025, USA
    Cancer Cell 19:257-72. 2011
    ..Therefore, carcinogenesis involves expansion and relocation of BM-niche cells to the tumor to create a niche to sustain cancer progression...
  24. ncbi Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis
    Markku Miettinen
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Arch Pathol Lab Med 130:1466-78. 2006
    ..They are believed to originate from interstitial cells of Cajal or related stem cells...
  25. ncbi E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer
    Fabio Petrocca
    Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA
    Cancer Cell 13:272-86. 2008
    ..Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer...
  26. pmc Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer
    Young Kook Kim
    Department of Biological Sciences, Seoul National University, Seoul, Korea
    Nucleic Acids Res 37:1672-81. 2009
    ..Our study demonstrates the functional associations between clustered miRNAs and further implicates that effective cancer treatment may require a combinatorial approach to target multiple oncogenic miRNA clusters...
  27. pmc MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor
    Jun Tie
    State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi an, Shaanxi, China
    PLoS Genet 6:e1000879. 2010
    ..Taken together, our results describe a Slit-miR-218-Robo1 regulatory circuit whose disruption may contribute to GC metastasis. Targeting miR-218 may provide a strategy for blocking tumor metastasis...
  28. ncbi Assessment of a HER2 scoring system for gastric cancer: results from a validation study
    M Hofmann
    Institute of Pathology, Klinikum Kassel, Kassel, Germany
    Histopathology 52:797-805. 2008
    ..The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric cancer...
  29. ncbi Interleukin-1 polymorphisms associated with increased risk of gastric cancer
    E M El-Omar
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    Nature 404:398-402. 2000
    ..Host genetic factors that affect interleukin-1-beta may determine why some individuals infected with H. pylori develop gastric cancer while others do not...
  30. ncbi Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer
    Mitsuru Sasako
    Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya, Hyogo, 663 8501, Japan
    J Clin Oncol 29:4387-93. 2011
    ..The results were therefore opened at the recommendation of an independent data and safety monitoring committee. We report 5-year follow-up data on patients enrolled onto the ACTS-GC study...
  31. ncbi miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells
    Lin Xia
    State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi an, People s Republic of China
    Int J Cancer 123:372-9. 2008
    ..Taken together, our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2...
  32. ncbi Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer
    Hanshao Liu
    National Engineering Center for Biochip at Shanghai, Shanghai, PR China
    Cancer Lett 316:196-203. 2012
    ..73% specificity in discriminating GC patients from healthy controls. Collectively, these data support our contention that serum miR-378 has strong potential as a novel noninvasive biomarker in gastric cancer detection...
  33. pmc Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer
    Ming Yang Song
    Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, People s Republic of China
    PLoS ONE 7:e33608. 2012
    ..To investigate the potential of serum miRNAs as biomarkers for early detection of gastric cancer (GC), a population-based study was conducted in Linqu, a high-risk area of GC in China...
  34. pmc Identification of gastric cancer stem cells using the cell surface marker CD44
    Shigeo Takaishi
    Division of Digestive and Liver Disease, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Stem Cells 27:1006-20. 2009
    ..These results support the existence of gastric CSCs and may provide novel approaches to the diagnosis and treatment of gastric cancer...
  35. ncbi MicroRNA dysregulation in gastric cancer: a new player enters the game
    W K K Wu
    Department of Medicine and Therapeutics, Institute of Digestive Diseases, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, PR China
    Oncogene 29:5761-71. 2010
    ..Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of gastric cancer and promote the development of miRNA-directed therapeutics against this deadly disease...
  36. ncbi MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin
    Tao Liu
    Tianjin Life Science Research Center, Tianjin Medical University, No 22, Qi Xiang Tai Road, Tianjin 300070, PR China
    Cancer Lett 273:233-42. 2009
    ..Down-regulation of prohibitin by miR-27a may explain why suppression of miR-27a can inhibit gastric cancer cell growth, further supporting that miR-27a functions as an oncogene...
  37. ncbi Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial)
    Hyung Ho Kim
    Seoul National University Bundang Hospital, Seongnam, Republic of Korea
    Ann Surg 251:417-20. 2010
    ..The aim of this study was to evaluate the safety of this trial with respect to morbidity and mortality...
  38. ncbi Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry
    Akiyoshi Hirayama
    Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan and National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Cancer Res 69:4918-25. 2009
    ....
  39. ncbi Recent patterns in gastric cancer: a global overview
    Paola Bertuccio
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Int J Cancer 125:666-73. 2009
    ..Steady downward trends persist in gastric cancer mortality worldwide even in middle aged population, and hence further appreciable declines are likely in the near future...
  40. pmc Epidemiology of gastric cancer
    Katherine D Crew
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, United States
    World J Gastroenterol 12:354-62. 2006
    ..The purpose of this review is to examine the epidemiology and risk factors of gastric cancer, and to discuss strategies for primary prevention...
  41. ncbi Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
    Kai Wang
    Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla, California, USA
    Nat Genet 43:1219-23. 2011
    ..These results reveal the genomic landscape, and highlight the importance of chromatin remodeling, in the molecular taxonomy of gastric cancer...
  42. ncbi Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial
    Jeeyun Lee
    Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Kangnam gu, Seoul 135 710 Korea
    J Clin Oncol 30:268-73. 2012
    ..This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP)...
  43. ncbi Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
    S Hirota
    Department of Pathology, Osaka University Medical School, Yamada oka 2 2, Suita 565, Japan
    Science 279:577-80. 1998
    ..GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34...
  44. ncbi Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data
    Anna D Wagner
    First Department of Medicine, Coordinating Centre for Clinical Trials, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    J Clin Oncol 24:2903-9. 2006
    ..This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer...
  45. ncbi Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective study
    Do Joong Park
    Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi Do, Seongnam si, Korea
    Surg Endosc 26:1548-53. 2012
    ..However, there were few reports on long-term outcomes of laparoscopy-assisted gastrectomy (LAG) for advanced gastric cancer (AGC). The aim of this study was to investigate long-term survival outcomes after LAG for AGC...
  46. ncbi Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer
    Mi Ran Jung
    Division of Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Gwangju, Korea
    J Surg Oncol 104:504-10. 2011
    ..Elevated neutrophil to lymphocyte ratio (N/L ratio) has been shown to be a prognostic indicator in various cancers. We aimed to investigate the prognostic significance of the preoperative N/L ratio in late stage gastric cancer...
  47. ncbi Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group
    Eric Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 24:4991-7. 2006
    ....
  48. ncbi Gastric cancer originating from bone marrow-derived cells
    JeanMarie Houghton
    Department of Medicine and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Science 306:1568-71. 2004
    ..These findings suggest that epithelial cancers can originate from marrow-derived sources and thus have broad implications for the multistep model of cancer progression...
  49. ncbi Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    Oncol Rep 25:1517-24. 2011
    ..However, the predictive role of MET amplification for treatment response should be further explored in upcoming clinical trials...
  50. pmc Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
    P Malfertheiner
    Otto von Guericke Universitat Magdeburg, Medizinische Fakultat, Zentrum fur Innere Medizin, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Gut 56:772-81. 2007
    ..Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000...
  51. ncbi Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance
    Yue Chen
    Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang 110001, People s Republic of China
    J Gastrointest Surg 14:1170-9. 2010
    ..MicroRNAs are endogenous small noncoding RNAs that aberrantly expressed in various carcinomas. MiR-148a and miR-152, which have the same "seed region", have not been comprehensively investigated in gastrointestinal cancers...
  52. ncbi A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis
    Rui Liu
    Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 210008, China
    Eur J Cancer 47:784-91. 2011
    ..The purpose of present study was to identify a serum microRNA (miRNA) expression profile that can serve as a novel diagnostic biomarker for GC detection and to assess its clinical applications in monitoring disease progression...
  53. ncbi MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
    Ling Ding
    The Center for Diseases Modeling and Program in Molecular and Cell Biology, Zhejiang University School of Medicine, Hangzhou, China
    Cell Res 20:784-93. 2010
    ..Thus, these data suggest that miR-375 may function as a tumor suppressor to regulate gastric cancer cell proliferation potentially by targeting the JAK2 oncogene, implicating a role of miR-375 in the pathogenesis of gastric cancer...
  54. pmc Endoscopic mucosal resection for treatment of early gastric cancer
    H Ono
    Department of Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Gut 48:225-9. 2001
    ..Bleeding and perforation (5%) were two major complications of EMR but there were no treatment related deaths. CONCLUSION: In our experience, EMR allows us to perform less invasive treatment without sacrificing the possibility of cure...
  55. pmc A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan
    Seigo Kitano
    Department of Surgery I, Oita University Faculty of Medicine, Yufu, Oita, Japan
    Ann Surg 245:68-72. 2007
    ..We conducted a retrospective, multicenter study of a large series of patients in Japan to evaluate the short- and long-term outcomes of laparoscopic gastrectomy for early gastric cancer (EGC)...
  56. pmc HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
    Ling Shan
    Department of Pathology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    Diagn Pathol 8:76. 2013
    ..In this study, the frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were examined in a large cohort of Chinese GC and GEJ cancer patients...
  57. ncbi Epstein-Barr virus: 40 years on
    Lawrence S Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, UK
    Nat Rev Cancer 4:757-68. 2004
    ..Despite such ubiquity, the link between EBV and 'endemic' Burkitt's lymphoma proved consistent and became the first of an unexpectedly wide range of associations discovered between this virus and tumours...
  58. pmc The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays
    Kambiz Sotoudeh
    Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran
    Diagn Pathol 7:57. 2012
    ..The aim of this study was to evaluate the frequency of c-MET overexpression and its relationship with clinicopathological variables in gastric cancer of Iranian population using tissue microarray...
  59. ncbi Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
    Marc Ychou
    Centre Regional de Lutte contre le Cancer Val d Aurelle, 298 rue des apothicaires 34298 Montpellier Cedex 05, France
    J Clin Oncol 29:1715-21. 2011
    ..This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma...
  60. ncbi Epidemiology of stomach cancer
    Hermann Brenner
    Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
    Methods Mol Biol 472:467-77. 2009
    ..Future epidemiologic research should pay particular attention to differentiation of stomach cancer epidemiology by subsite, and to exploration of potential interactions between H. pylori infection, genetic, and environmental factors...
  61. ncbi HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    C Gravalos
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    Ann Oncol 19:1523-9. 2008
    ..This review summarizes the rationale, preclinical evidence, retrospective clinical analyses, and the interim clinical data pertaining HER2 therapies in gastric cancer...
  62. ncbi Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up
    Markku Miettinen
    Departments of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Am J Surg Pathol 29:52-68. 2005
    ..The above results may be helpful for setting the criteria for adjuvant treatment such as Gleevec...
  63. ncbi miR-21 plays a pivotal role in gastric cancer pathogenesis and progression
    Zhiyu Zhang
    1Department of Gastroenterology, Shanghai Renji Hospital, Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine, Shanghai, China
    Lab Invest 88:1358-66. 2008
    ..Our findings suggest a potential regulatory pathway in which H. pylori infection upregulates expression of miR-21, which in turn downregulates RECK, and then leads to the development of gastric cancer...
  64. ncbi Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
    M Tanner
    Laboratory of Cancer Biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN 33101 Tampere, Finland
    Ann Oncol 16:273-8. 2005
    ..HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab. We wanted to investigate the frequency and clinical significance of HER-2/neu amplification in gastric carcinoma...
  65. doi Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer
    Hiromi Sakamoto
    Nat Genet 40:730-40. 2008
    ..90, 95% CI = 1.56-2.33, P = 8.01 x 10(-11)). The polymorphism of the PSCA gene, which is possibly involved in regulating gastric epithelial-cell proliferation, influences susceptibility to diffuse-type gastric cancer...
  66. pmc MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation
    Yong Xi Song
    Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City 110001, China
    Mol Cancer 10:1. 2011
    ..The purpose of this study was to elucidate the molecular mechanisms by which miR-148b acts as a tumor suppressor in gastric cancer...
  67. ncbi Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis
    HuiPing Xue
    Department of Gastroenterology, Shanghai Institute of Gastrointestinal Diseases, Shanghai, China
    J Gastroenterol Hepatol 25:1604-17. 2010
    ....
  68. ncbi Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
    ..Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage...
  69. pmc Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line
    Keiichi Ohshima
    Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan
    PLoS ONE 5:e13247. 2010
    ..Thus, profiling exosomal miRNAs are in need to clarify intercellular signaling and discover a novel disease marker as well...
  70. ncbi Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial
    Kazutoshi Fukase
    Department of Gastroenterology, Yamagata Prefectural Central Hospital, Yamagata, Japan
    Lancet 372:392-7. 2008
    ..Our aim was to investigate the prophylactic effect of H pylori eradication on the development of metachronous gastric carcinoma after endoscopic resection for early gastric cancer...
  71. ncbi Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor
    H K Kim
    Hematologic Malignancies Branch, Division of Special Cancers, National Cancer Center, 809 Madu 1 dong, Ilsan gu, Goyang, 411 764, Gyeonggi, South Korea
    Eur J Cancer 39:184-91. 2003
    ....
  72. pmc Helicobacter pylori: gastric cancer and beyond
    D Brent Polk
    Department of Pediatrics, University of Southern California, Los Angeles, CA 10027, USA
    Nat Rev Cancer 10:403-14. 2010
    ..pylori-infected human populations at increased risk for stomach cancer but will also provide mechanistic insights into inflammatory carcinomas that develop beyond the gastric niche...
  73. ncbi Molecular-pathological prognostic factors of gastric cancer: a review
    Wataru Yasui
    Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8551, Japan
    Gastric Cancer 8:86-94. 2005
    ..A combination of these examinations can not only foretell a patient's prognosis but can also give information directly connected with personalized cancer medicine and prevention...
  74. ncbi Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial
    Benjamin Chun Yu Wong
    Department of Medicine, University of Hong Kong, Hong Kong, China
    JAMA 291:187-94. 2004
    ..Although chronic Helicobacter pylori infection is associated with gastric cancer, the effect of H pylori treatment on prevention of gastric cancer development in chronic carriers is unknown...
  75. ncbi Gastric cancer
    Vincenzo Catalano
    SOC Oncologia Medica, Azienda Ospedaliera Ospedale San Salvatore, Via C Lombroso 1, 61100 Pesaro, Italy catalano
    Crit Rev Oncol Hematol 71:127-64. 2009
    ..This review summarizes the most important recommendations for the management of patients with gastric cancer...
  76. ncbi Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?
    Lorenzo Fuccio
    University of Bologna, Bologna, Italy
    Ann Intern Med 151:121-8. 2009
    ..Helicobacter pylori infection is associated with gastric cancer, but the effect of eradication treatment on gastric cancer risk is not well defined...
  77. ncbi Molecular pathology of gastric carcinoma
    Bo Gun Jang
    Department of Pathology and Cancer Research Institute, Seoul National University College of Medicine, Korea
    Pathobiology 78:302-10. 2011
    ..A genome-wide search has been undertaken to identify novel methylation-silenced genes in GC, which will help us understand the overall molecular features of GC and further provide novel opportunities in the treatment of GC...
  78. ncbi Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms
    Emad M El-Omar
    Department of Medicine and Therapeutics, Aberdeen University, Foresterhill, Scotland
    Gastroenterology 124:1193-201. 2003
    ..The aim of this study was to evaluate the role of proinflammatory cytokine gene polymorphisms in gastric and esophageal cancers defined by anatomic subsite...
  79. pmc Helicobacter pylori and gastric cancer: factors that modulate disease risk
    Lydia E Wroblewski
    Division of Gastroenterology, Vanderbilt University School of Medicine, 2215 Garland Ave, 1030C MRB IV, Nashville, TN 37232 2279, USA
    Clin Microbiol Rev 23:713-39. 2010
    ..Since H. pylori inhibits the gastric epithelium of half of the world, it is crucial that we continue to gain understanding of host and microbial factors that increase the risk of developing more severe clinical outcomes...
  80. ncbi Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction
    Michael Stahl
    Department of Medical Oncology and Hematology, Kliniken Essen Mitte, Henricistr 92, D 45136 Essen, Germany
    J Clin Oncol 27:851-6. 2009
    ..Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown...
  81. pmc MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
    Jochen K Lennerz
    Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 29:4803-10. 2011
    ..We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study...
  82. ncbi The prevalence of Th17 cells in patients with gastric cancer
    Bin Zhang
    Department of General Surgery, Changhai Hospital, The Second Military Medical University, No 168, Changhai Road, Shanghai 200433, PR China
    Biochem Biophys Res Commun 374:533-7. 2008
    ..The results indicate that Th17 cells may contribute to gastric cancer pathogenesis...
  83. ncbi Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome
    Maria D Begnami
    Department of Pathology, Hospital A C Camargo, Rua Professor Antonio Prudente 211, Liberdade, Sa Paulo, Brazil
    J Clin Oncol 29:3030-6. 2011
    ..The effect of HER3 or HER4 expression in GC has not been sufficiently studied. In this study, we explored the gene and protein expression of the HER family in GC to establish new potential prognostic factors...
  84. ncbi Survival prediction of gastric cancer by a seven-microRNA signature
    Xiaohua Li
    State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, 17 Changle Western Road, Xi an, China
    Gut 59:579-85. 2010
    ..No study has evaluated the association between miRNA expression patterns and gastric cancer prognosis. In this study, we developed a seven-miRNA signature that is closely associated with survival of patients with gastric cancer...
  85. ncbi miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3
    Xiaohua Li
    State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi an 710032, China
    Mol Cancer Res 9:824-33. 2011
    ..These findings indicate a new regulatory mode, namely, specific miRNA, which is activated by its upstream transcription factor, could suppress its direct targets and lead to tumor invasion and metastasis...
  86. ncbi The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea
    Jung Mook Kang
    Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
    J Clin Gastroenterol 43:420-8. 2009
    ..The present study was performed to evaluate whether or not the genetic polymorphisms of IL-6, IL-8, and IL-10 are associated with gastroduodenal disease in the Korean population...
  87. ncbi X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis
    HuiPing Xue
    Department of Gastroenterology, Renji Hospital, Shanghai Institute of Gastrointestinal Diseases, School of Medicine, Shanghai Jiaotong University, People s Republic of China
    Am J Epidemiol 173:363-75. 2011
    ..The Arg399Gln SNP is not associated with the cardia type of gastric cancer. Evidently, the heterogeneity regarding the Arg399Gln SNP across studies is not explained by ethnicity, genotyping technique, sample size, or date of publication...
  88. ncbi Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer
    Hong Mei Nan
    Department of Preventive Medicine, College of Medicine, Chungbuk National University, 12 Kaeshin dong, Hungdok gu, Cheongju Si, Chungbuk 361 763, Republic of Korea
    World J Gastroenterol 11:3834-41. 2005
    ..The purpose of this study was to investigate the effects of environmental factors, genetic polymorphisms of major metabolic enzymes, and microsatellite instability on hypermethylation of the promoter of the hMLH1 gene in gastric cancer...
  89. ncbi Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer
    Toshihiko Doi
    National Cancer Center Hospital East, 5 1, Kashiwanoha 6 chome, Kashiwa shi, Chiba 277 8577, Japan
    J Clin Oncol 28:1904-10. 2010
    ..Adverse events are consistent with the reported safety profile of everolimus. These results warrant further evaluation in patients with advanced gastric cancer...
  90. ncbi Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma
    Min A Kim
    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
    Histopathology 54:442-51. 2009
    ..EMT is known to be involved in the progression and metastasis of various cancers. The aim was to evaluate the expression of EMT-related proteins in gastric carcinoma (GC)...
  91. ncbi Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas
    Jing Zhao
    Fourth Laboratory of Cancer Institute, Department of Tumor Pathology of General Surgery Institute, No 1 Hospital of China Medical University, Shenyang, Liaoning Province, China
    Histol Histopathol 26:1111-20. 2011
    ..Our findings also demonstrated that combined detection of these two tumor-specific biomarkers in gastric carcinomas can provide additional efficacy in predicting the patients' outcomes...
  92. ncbi Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
    J Lagergren
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 340:825-31. 1999
    ..The causes of adenocarcinomas of the esophagus and gastric cardia are poorly understood. We conducted an epidemiologic investigation of the possible association between gastroesophageal reflux and these tumors...
  93. ncbi Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells
    N Murata-Kamiya
    Division of Molecular Oncology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Oncogene 26:4617-26. 2007
    ..pylori CagA plays an important role in the development of intestinal metaplasia, a premalignant transdifferentiation of gastric epithelial cells from which intestinal-type gastric adenocarcinoma arises...
  94. pmc Sequential expression of putative stem cell markers in gastric carcinogenesis
    T Wang
    Cancer Science Institute, National University Health System and Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Br J Cancer 105:658-65. 2011
    ..Gastric carcinogenesis has been well documented in the step-wise histopathological model, known as Correa pathway. Several biomarkers including CD44, Musashi-1 and CD133 have been reported as putative stem cell (PSC) markers...
  95. ncbi Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer
    Elena Rossi
    Biology and Medical Genetics, University of Pavia, 27100 Pavia, Italy
    Hum Pathol 42:1937-45. 2011
    ..We conclude that genome-wide array comparative genomic hybridization of gastric cancer contributes prognostically relevant information providing a genetic background for histologic grading...
  96. ncbi Possible associations of APE1 polymorphism with susceptibility and HOGG1 polymorphism with prognosis in gastric cancer
    Emel Canbay
    General Surgery, Basaksehir State Hospital, Basaksehir, Istanbul, 34230, Turkey
    Anticancer Res 30:1359-64. 2010
    ..In this study, we examined the polymorphisms of six DNA repair genes: APE1, HOGG1, XRCC1, XRCC3, XPD, and XPG in patients with gastric cancer (GC)...
  97. ncbi Targeted HER2 treatment in advanced gastric cancer
    Jan Trøst Jørgensen
    Dx Rx Institute, Baunevaenget 76, DK 3480 Fredensborg, Denmark
    Oncology 78:26-33. 2010
    ....
  98. pmc Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group
    A Cuschieri
    University Department of Surgery, Ninewells Hospital and Medical School, Dundee, UK
    Br J Cancer 79:1522-30. 1999
    ..However, the possibility that D2 resection without pancreatico-splenectomy may be better than standard D1 resection cannot be dismissed by the results of this trial...
  99. pmc Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
    J D Barros-Silva
    Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
    Br J Cancer 100:487-93. 2009
    ....
  100. ncbi HER-2 amplification is highly homogenous in gastric cancer
    Andreas H Marx
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Germany
    Hum Pathol 40:769-77. 2009
    ..The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas...
  101. ncbi Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer
    Domenico Palli
    Molecular and Nutritional Epidemiology Unit, ISPO Cancer Prevention and Research Institute, Via Cosimo il Vecchio 2, 50139 Florence, Italy
    Mutagenesis 25:569-75. 2010
    ..25, P=0.0012). These findings indicate that a complex interaction between host factors such as oxidative stress, antioxidant capacity and efficiency of multiple DNA repair pathways underlies the inter-individual variability in GC risk...

Research Grants29

  1. Analysis of the H. Pylori cag pathogenicity island
    Timothy L Cover; Fiscal Year: 2012
    ..This research seeks to understand how a bacterial infection can lead to these diseases. The long-term goals are to develop effective means for the prevention and treatment of stomach cancer and peptic ulcer disease. ..
  2. Surrogate Biomarkers of Micrometastatic Gastric Cancer
    Adam Smolka; Fiscal Year: 2004
    ..The successful development and validation of a lymph node RT-PCR-based assay for micrometastatic stomach cancer is likely to have a significant clinical impact. ..
  3. PHENOTYPIC AND PSYCHOSOCIAL STUDY OF THE L1307K MUTATION
    Henry Lynch; Fiscal Year: 2004
    ....
  4. PHARMACOLOGY OF ANTICANCER DRUGS IN ADVANCED AGE
    HEINZ LENZ; Fiscal Year: 2003
    ....
  5. PROJECT ALLIFE-EXERCISE AND LEUKEMIA SURVIVORS
    Kevin Oeffinger; Fiscal Year: 2006
    ..This study will represent the first clinical trial aimed at increasing physical activity in leukemia survivors and will advance our understanding of this vulnerable population. ..
  6. DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY
    HEINZ LENZ; Fiscal Year: 2004
    ..This proposal will feature three beginning clinicians responsible for three different patient oriented projects taking advantage of our successful program in molecular outcome research. ..
  7. Microtubule-targeting and regulation of HIF-1
    Paraskevi Giannakakou; Fiscal Year: 2009
    ..abstract_text> ..
  8. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  9. Antitubulin drugs: Mechanisms of action and resistance
    Paraskevi Giannakakou; Fiscal Year: 2007
    ..We will also perform molecular modeling and structural studies of discodermolide-tubulin binding (c) Introduce specific tubulin mutations into human cancer cells to investigate their effect on drug-binding. ..
  10. Mammography and High-Risk Survivors of Pediatric Cancer
    Kevin Oeffinger; Fiscal Year: 2005
    ....
  11. Rectal Cancer: Molecular Markers of Outcome and Toxicity
    Heinz Josef Lenz; Fiscal Year: 2007
    ..Results from this study may aid in the development of future treatment strategies for patients with rectal cancer. ..
  12. DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS
    HEINZ LENZ; Fiscal Year: 2002
    ....
  13. H. PYLORI-SPECIFIC REGULATORY T CELLS THAT LIMIT HOST RESPONSE
    Thomas Blanchard; Fiscal Year: 2008
    ..These studies will increase our understanding of gastrointestinal immunoregulation and the design of better immunotherapies. ..
  14. Olympus FV1000 Confocal Fluorescence Microscope
    James Goldenring; Fiscal Year: 2007
    ..Confocal fluorescence microscopy, especially in its uses for the study of living cells, holds the key to performing all of these studies. PHS 398/2590 (Rev. 09/04) [unreadable] [unreadable] [unreadable]..
  15. Gastrointestinal Tract X FASEB Conference
    James Goldenring; Fiscal Year: 2003
    ..abstract_text> ..
  16. Rab25 in the Pathogenesis of Ichthyosis Vulgaris
    James Goldenring; Fiscal Year: 2003
    ..In addition, it will provide the first investigations of alterations in membrane recycling in skin diseases. ..
  17. HELICOBACTER INFECTION AND GROWTH OF CHILDREN
    Pelayo Correa; Fiscal Year: 2001
    ..pylori infection and growth retardation, essential information for evaluating the effects of H. pylori infection on children's health and targeting appropriate preventive strategies. ..
  18. THE ROLE OF MYCOBACTERIA IN CROHN'S DISEASE
    David Graham; Fiscal Year: 2005
    ..The results of this study should either confirm or refute the proposed etiologic association of M. paratuberculosis and Crohn's disease as well as the identification of patients with Crohn's disease and M. paratuberculosis. ..
  19. Molecular strategies to define carcinoids and rationalize surgical intervention
    Irvin Modlin; Fiscal Year: 2009
    ..This will provide novel biological information and provide molecular data to identify occult metastasis predict spread and facilitate preemptive appropriate therapy. ..
  20. Endoscopic Therapy of Early Cancer in Barretts Esophagus
    Kenneth Wang; Fiscal Year: 2009
    ..Diagnostic and therapeutic techniques developed in this study can be applied to other gastrointestinal tumors. ..
  21. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  22. Molecular Strategies for Gastric Carcinoid Surgery
    Irvin Modlin; Fiscal Year: 2005
    ..A pre-operative determination of the neoplastic ECL cell gene expression relating to gastrin responsiveness will improve the rationale for therapeutic gastric or antral resection. ..
  23. Novel Method of Surveillance in Barrett's Esophagus
    Kenneth Wang; Fiscal Year: 2008
    ..This is an innovative method by which a physician can diagnose hidden areas of cancer within patients who are at a high risk of developing esophageal cancer. [unreadable] [unreadable] [unreadable]..
  24. iNOS, COX-2, and Arginase in Murine Barrett's Esophagus
    Keith Wilson; Fiscal Year: 2003
    ..We will study macroscopic and histologic evidence of esophagitis, BE and BAA, gene expression, apoptosis and proliferation in A. wild-type (WT) vs. COX-2-/- mice, B. W'I- vs. iNOS -/-mice, and C. WT vs. argll -/- mice. ..
  25. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  26. Inhibition of pathogen-induced NFkBmediated inflammation
    Richard Peek; Fiscal Year: 2005
    ..2)To identify and functionally characterize PPAR( target genes and microbially-induced NF-?B-regulated genes that are suppressed by PPAR(, activation using an in vitro model of intestinal epithelial cell inflammation. ..
  27. Biomarkers in Phototherapy of Barrett's Esophagus
    Kenneth K Wang; Fiscal Year: 2010
    ..These studies will provide an improved understanding regarding the response of Barrett's esophagus to ablation therapy. ..
  28. A NOVEL TECHNIQUE FOR SCREENING BARRETT'S ESOSPHAGUS
    Kenneth Wang; Fiscal Year: 2003
    ..The development of a screening device for Barrett's esophagus that could be operated by paramedical personnel would enable large-scale low cost screening to identify patients at risk for esophageal cancer. ..
  29. Mechanism that regulate Helicobacter pylori-induced beta-caterin activation
    Richard Peek; Fiscal Year: 2009
    ..py/ori-induced B-catenin activation. 3. To define differences in epithelial molecular responses to carcinogenic H. pylori versus mutant strains using a transgenic murine model of gastric cancer. ..